New Indication: Polatuzumab in Untreated DLBCL


  • Study

    Double-blind Phase III trial
    Untreated intermediate-risk or high-risk DLBCL
    Polatuzumab-R-CHP vs R-CHOP



  • Efficacy

    2 years PFS: 76.7% vs 70.2% (HR:0.73 95% Cl 0.57-0.95 p=0.02)
    2 years OS: 88.7% vs 88.6% (HR:0.94 95% Cl 0.65-1.37 p=0.75)



  • Safety

    Any grades AEs: All 97.9% vs 98.4%,
    Grade >=3 AEs: 60.7% vs 59.8%
    Serious AEs:34.0% vs 30.6%
    Grade 5 AEs: 3.0% vs 2.3%



  • N Engl J Med 2022; 386:351-363

    Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    http://doi.org/10.1056/NEJMoa2115304

    Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022